Shots: The MHLW has approved the expanded use of FoundationOne CDx for Rozlytrek to treat ROS1 fusion-positive, LA/ m-NSCLC, allowing the physician to identify NSCLC patients who could benefit from […]readmore
Tags : Entrectinib
Shots: The US FDA has granted approval to Rozlytrek for ROS1-positive m-NSCLC in adults and accelerated approval for solid tumors having NTRK gene fusion in adults & pediatric patients aged≥ […]readmore
Shots: The approval is based on P-II STARTRK-2, P-I STARTRK-1, P-I ALKA-372-001 & P-I/II STARTRK-NG studies results assessing Rozlytrek in adults & pediatric patients with NTRK fusion-positive solid tumors, across […]readmore
Shots: The FDA’s PR designation to the combination of Polatuzumab Vedotin + bendamustine (B)+ Rituxan (rituximab, R) vs BR as monothx & Entrectinib are based on GO29365 & STARTRK (1,2, […]readmore